Treatment failure resulting from resistance of staphylococcus aureus to daptomycin.
Author Department
Medicine
Document Type
Article, Peer-reviewed
Publication Date
2-1-2006
Abstract
Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resi
Publication ISSN
0884-8734
Recommended Citation
J Clin Microbiol. 2006 Feb;44(2):655-656.
COinS